Corteva Inc. Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Corteva Inc. Common Stock trades at $13.82 (market cap $9.64B), while Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M). The key difference: Corteva Inc. Common Stock is far larger — about 80.7× Inovio Pharmaceuticals Inc's market cap, and Corteva Inc. Common Stock pays a 4.98% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corteva Inc. Common Stock for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| CTVA | INO | |
|---|---|---|
Market Cap | $9.64B | $119.42M |
Volume | 41,241,255 | 2,789,649 |
Sector | Basic Materials | Health |
52-Week High | $90.51 | $2.65 |
52-Week Low | $11.92 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $12.15B | $90.75M |
Dividend Yield | 4.98% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Corteva provides seeds, crop protection products, and digital tools for agriculture. Its products are used by farmers to manage crop production and protect yields.
Read more on CTVA →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →